99Z.F MODUS THERAPEUTICS HLDG

Healthcare Biotechnology Frankfurt Exchange
0.0032 EUR
Close of Nov 10, 2026
0.0024 0.0384
Market cap
EUR 541K
P/E
-
P/B
0.58x
ROE
-154.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 99Z.F undervalued?

Graham number

The Graham number of MODUS THERAPEUTICS HLDG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MODUS THERAPEUTICS HLDG fundamental analysis

No fundamental analysis for MODUS THERAPEUTICS HLDG yet.

MODUS THERAPEUTICS HLDG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MODUS THERAPEUTICS HLDG

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.

Full company profile